Lineage Cell Therapeutics (LCTX) Cash from Investing Activities Growth (3y) (2013 - 2026)
Lineage Cell Therapeutics (LCTX) Cash from Investing Activities Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | -29.84% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 38.24% |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | -22.09% |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Lineage Cell Therapeutics | 251.15 Mn | 188.44 Mn | 1.73 Mn | -29.08% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -29.08% |
| Dec 31, 2025 | -44.31% |
| Sep 30, 2025 | 93.36% |
| Jun 30, 2025 | 47.55% |
| Mar 31, 2025 | 251.34% |
| Dec 31, 2024 | 171.66% |
| Sep 30, 2024 | 289.69% |
| Jun 30, 2024 | -324.44% |
| Mar 31, 2024 | -26.07% |
| Dec 31, 2023 | 121.04% |
| Sep 30, 2023 | 128.44% |
| Jun 30, 2023 | 41.92% |
| Mar 31, 2023 | 43.17% |
| Dec 31, 2022 | -108.67% |
| Sep 30, 2022 | -71.38% |
| Jun 30, 2022 | 20.63% |
| Mar 31, 2022 | -26.32% |
| Dec 31, 2021 | -26.30% |
| Sep 30, 2021 | 21.02% |
| Jun 30, 2021 | -41.03% |